Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Matt Heimermann
Period: Reporting periods mapped to calendar 2025 Q3 – 2026 Q2 (4 quarters).
- Questions
- 16on tracked calls
- Challenge rate
- 0%none of 16 questions
- Companies
- 4questioned at least once
- Reporting periods
- 4with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 16 of 16 questions from 4 companies
CBChubb Limited8 questions · 4 reporting periods · 0 of 8 challenging
Calendar 2026 Q2
I'm curious what they see that might be different than what you're seeing
Show response
Greenberg declined to speculate on rivals' views, reiterating confidence in Chubb's diversification to outperform regardless of market conditions.
In Singapore, there were some regulatory changes to deductible levels for accident health products.
Show response
Greenberg said the Singapore supplemental-health and Hong Kong flow changes had no impact and expects none going forward, calling the Hong Kong reaction overblown.
Calendar 2026 Q1
Just how to think about how likely additional opportunistic reinsurance purchases are?
Show response
Greenberg kept answer high-level, describing reinsurance as one of several tools for managing exposure appetite when pricing is marginal, without committing to specific plans.
does that create some flexibility to take more risk asset side?
Show response
Greenberg firmly rejected the premise of a risk trade-off between underwriting and investment sides, saying they have plenty of capital and optimize each independently.
Calendar 2025 Q4
you had this comment with respect to more favorable January 1 conditions relative to expectations
Show response
Evan: not geopolitical; large-account book in US/UK/Europe at Jan 1 did better than internal expectations. Statement of confidence for a good start to the year, not a growth callout.
when you think about the pace at which you're moving on that, how constrained are you at all, if at all, by other stakeholders
Show response
Evan: digital partner priorities for their own growth can slow connectivity/data/analytics buildout. Only significant external constraint. Also noted December dinner was long-term intrinsic value framing, not quarterly update fodder.
Calendar 2025 Q3
there's been a lot of chatter about a particular historically wholesale broker moving into the U.S. organically on the retail side
Show response
Evan: dynamic free-market choice; glad regulation doesn't block rational market decisions. No concern about the broker behavior.
I wonder if you could talk maybe about the inorganic growth opportunities in Asia
Show response
Evan dismissed the seller narrative; says Chubb's dance card is full with organic growth opportunities across consumer and SME in many Asian countries.
ACGLArch Capital Group4 questions · 2 reporting periods · 0 of 4 challenging
Calendar 2026 Q1
I just wanted to follow up on your call related to using AI in the technology rollover of mid-corp.
Show response
Nicolas explained AI helped in two ways: writing code and accelerating testing (running scenarios to validate software behavior). Francois noted this was unusual, they built a brand-new platform infrastructure from scratch since they bought the business without systems. AI capabilities significantly sped up the process.
Calendar 2025 Q4
Any opportunistic investments you're thinking about making in tech or ops or accelerating existing investments?
Show response
Francois said no direct tech investments from QRTCs, investments made based on business needs. QRTCs reinforce the value of Bermuda presence. Nicolas added QRTCs are really an offset to the high cost of doing business in Bermuda.
I'd be curious about the margin consequences of that.
Show response
Francois said shedding worst-performing programs should improve margins, but market conditions create uncertainty on net impact. Nicolas added some shed programs were cat-exposed, poor capital allocation despite acceptable upfront results. Still expects insurance to run in the low nineties combined ratio.
I'm just curious whether or not you're you're you're seeing any noticeable signal or information there that's worth calling out
Show response
Nicolas said subject premium revisions are happening in other property (E&S property, energy) where companies had to revise growth projections down. Casualty is different, demand decline is from cedents retaining more, not underlying business shrinking. Francois added they actively monitor premium projections quarterly to avoid large downward adjustments.
BROBrown & Brown3 questions · 2 reporting periods · 0 of 3 challenging
Calendar 2026 Q2
could cause the expenses associated with McKinsey Accenture and Anthropic to be higher than kind of the reallocation
Show response
Identified pace of organizational change as the swing factor and reaffirmed that projected spend can be absorbed within current margins.
Calendar 2025 Q3
You had rolled out or started to roll out private flood product on that platform. I'm just curious how the initial uptake is going on that
Show response
Powell discussed Polten acquisition (private flood, closing 11/1), cautioned private flood isn't universal solution, expressed confidence in NFIP renewal resolution in near-to-intermediate term.
I feel like there's a number of cross currents affecting the business
Show response
Powell explained smaller group per-head-per-month compensation limits growth without headcount adds. Companies modifying plans to manage costs, especially GLP-1 drug spend. Emphasized multi-year strategic approach to health care.
EGEverest Group1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q2
we should expect a natural shortening of the duration on the investment portfolio side
Show response
Habayeb explained the liability-driven approach and gave the current asset duration of about 3.5 years with a tight ALM match.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| CB Chubb Limited | 8 | 0%none of 8 questions |
| ACGL Arch Capital Group | 4 | 0%none of 4 questions |
| BRO Brown & Brown | 3 | 0%none of 3 questions |
| EG Everest Group | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q3 | 4 | 0%none of 4 questions | 2 |
| 2025 Q4 | 5 | 0%none of 5 questions | 2 |
| 2026 Q1 | 3 | 0%none of 3 questions | 2 |
| 2026 Q2 | 4 | 0%none of 4 questions | 3 |
- 2025 Q34 questions · challenge rate 0% (none of 4 questions) · 2 companies
- 2025 Q45 questions · challenge rate 0% (none of 5 questions) · 2 companies
- 2026 Q13 questions · challenge rate 0% (none of 3 questions) · 2 companies
- 2026 Q24 questions · challenge rate 0% (none of 4 questions) · 3 companies
Topics
Topics tagged on this analyst’s questions.
- Competitive Dynamics5
- Regulation Policy4
- Pricing3
- Capital Allocation3
- Innovation & R&D3
- M&A3
- Revenue Growth2
- Demand2
- Cloud & AI1
- Cost Pressure1
Show all 15 topics
- Capex Investment1
- Credit1
- Margin1
- Macroeconomic1
- Geographic Expansion1